Today: 30 June 2026
Browse Category

NYSE:NVO 6 January 2026 - 23 January 2026

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

NEW YORK, January 17, 2026, 14:16 EST — The market has closed. U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week.
17 January 2026
······
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

New York, Jan 13, 2026, 10:50 — Regular session Pfizer Inc shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase 3 trials for its Metsera obesity drugs by the end of 2026. The company has indicated it doesn’t expect revenue growth to resume until 2029.
13 January 2026
····
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

New York, January 12, 2026, 20:17 — Market closed. Pfizer Inc. shares fell on Monday after Chief Executive Albert Bourla said the cash-pay market for obesity drugs — where patients pay out of pocket — now works “almost like Viagra”, the erectile-dysfunction drug Pfizer launched in 1998. The company, which bought obesity developer Metsera in a deal valued at up to $10 billion and has said it does not expect to return to revenue growth until 2029, closed down 0.8% at $25.27.
13 January 2026
···
Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill

Novo Nordisk gets a fresh $73.50 target as Amazon starts selling the Wegovy pill

CICC initiated coverage on Novo Nordisk’s U.S.-listed American depositary receipt — a U.S.-traded certificate that represents shares in a foreign company — with an outperform rating and a $73.50 price target, a Finwire report carried by MarketScreener showed on Friday. Novo’s Copenhagen-listed stock was up about 3%. The call lands as Novo tries to widen access to Wegovy in pill form, a key test for the maker of Ozempic after profit warnings and sliding shares last year. Investors have watched Eli Lilly pull ahead in the U.S. obesity market, and any hint of steadier growth is getting airtime.
9 January 2026
·
Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy said on Friday it now offers Novo Nordisk’s Wegovy weight-loss pill through insurance plans and a cash-pay option, with uninsured customers paying from $149 a month and some commercially insured customers paying $25 for a one-month supply. Amazon said it will add the pill to its pharmacy kiosks in the coming weeks and is working with telehealth firms including WeightWatchers, Wheel and 9amHealth; Novo has said the pill will also be available through CVS, Costco and other telehealth services such as Ro, LifeMD and GoodRx. The U.S. FDA approved the once-daily semaglutide pill in December; semaglutide is the active ingredient in injectable Wegovy and diabetes drug Ozempic, and Reuters said the pill’s success is tied to cash-paying consumers who cannot get coverage. That shift matters because obesity drugs have mostly been sold through insurers, with list prices and rebates doing the messy work in the background. A simple “pay cash, get the pill” offer, pushed through a major retail channel, tests how much demand sits outside the usual reimbursement system — and how fast drugmakers will have to adjust.
9 January 2026
···
Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

NEW YORK, Jan 9, 2026, 09:35 EST — Regular session Amazon Pharmacy said it now offers Novo Nordisk’s Wegovy pill through insurance plans and a cash-pay option, widening its push into prescription drugs as demand for weight-loss treatments spreads beyond injections. Eligible customers with commercial insurance may pay as little as $25 for a one-month supply, while customers without insurance can buy the pill starting at $149 per month; U.S. regulators approved the 25-milligram semaglutide pill in December, the company said. Amazon.com shares were down 0.7% at $244.58 in early New York trade.
9 January 2026
···
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

NEW YORK, Jan 9, 2026, 07:03 EST — Premarket Novo Nordisk’s U.S.-listed shares gained 1.4% to $57.34 in premarket trading on Friday after the company rejected claims involving SaveRxCanada.to, a Canadian online pharmacy platform that says it offers India-sourced Ozempic to U.S. patients. SaveRxCanada.to said the pens start at about $280 each, compared with typical U.S. retail prices of $900 to $1,100. A Novo spokesperson said: “We have no customer or partner relationship with this company/platform, and Ozempic from India has not been provided to them.”
9 January 2026
···
1 2 3 4 5 … 7

Stock Market Today

  • Talawar Therapeutics to List Nasdaq as It Raises $285M for Atopic Dermatitis Drug
    June 30, 2026, 8:18 AM EDT. Talawar Therapeutics will go public on Nasdaq as 'TLWR' after pulling in $225 million through a PIPE plus $60 million from SPAC JATT II Acquisition, raising $285 million in total. The New Jersey biotech is developing TALA-125, an IL-13/IL-18 bispecific antibody aimed at atopic dermatitis, and is going up against Sanofi and Regeneron's top-selling Dupixent. Talawar says this new approach could get past limits of current therapies by targeting two immune pathways. The company expects to start Phase IIb trials by early 2027, with data coming in late 2028. AD sales could hit $22.4 billion by 2033, even as the field still sees unmet need.
Go toTop